<?xml version="1.1" encoding="utf-8"?>
<rdf:RDF xmlns:OMEXlib="http://omex-library.org/"
   xmlns:bqbiol="http://biomodels.net/biology-qualifiers/"
   xmlns:bqmodel="http://biomodels.net/model-qualifiers/"
   xmlns:dc="http://purl.org/dc/terms/"
   xmlns:foaf="http://xmlns.com/foaf/0.1/"
   xmlns:local="http://omex-library.org/NewOmex.omex/NewModel.rdf#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#">
  <rdf:Description rdf:about="http://omex-library.org/BIOMD0000000621.omex">
    <bqmodel:isDescribedBy rdf:resource="local:00001"/>
    <ns1:keyword xmlns:ns1="http://prismstandard.org/namespaces/basic/2.0/">Biomodels</ns1:keyword>
    <ns2:description xmlns:ns2="http://purl.org/dc/elements/1.1/">&lt;body xmlns="http://www.w3.org/1999/xhtml"&gt;
  &lt;div class="dc:title"&gt;Palmer2014 - Effect of IL-1β-Blocking therapies in T2DM - Healthy Condition&lt;/div&gt;
  &lt;div class="dc:description"&gt;
    &lt;div&gt;
      &lt;p&gt;
          This is the model with healthy state initial conditions. A few changes were made to the model equations in order to bypass the circular dependencies apparent in SBML. Coupled algebraic equations for the species Glucose, Insulin and Proinsulin were changed to reactions which represent the ordinary differential equations found in a previously published model by &lt;a href="http://europepmc.org/abstract/MED/18780774"&gt;De Gaetano
et al (2008)&lt;/a&gt;, &lt;a href="http://www.ebi.ac.uk/biomodels-main/MODEL1112110003" title="BioModels Entry"&gt;[MODEL1112110003]&lt;/a&gt;. This reference was used by the present authors for the algebraic equations. The original Mathematica code, obtained from the supplementary material of the article can be downloaded from the link below: 
      [&lt;a href="http://www.ebi.ac.uk/biomodels/models/MODEL1604270002/Palmer2014_notebook.nb"&gt;Palmer2014_notebook.nb&lt;/a&gt;].
	    &lt;/p&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div class="dc:bibliographicCitation"&gt;
    &lt;p&gt;This model is described in the article:&lt;/p&gt;
    &lt;div class="bibo:title"&gt;
      &lt;a href="http://identifiers.org/pubmed/24918743" title="Access to this publication"&gt;Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms.&lt;/a&gt;
    &lt;/div&gt;
    &lt;div class="bibo:authorList"&gt;Palmér R, Nyman E, Penney M, Marley A, Cedersund G, Agoram B.&lt;/div&gt;
    &lt;div class="bibo:Journal"&gt;CPT Pharmacometrics Syst Pharmacol. 2014 Jun 11;3:e118. &lt;/div&gt;
    &lt;p&gt;Abstract:&lt;/p&gt;
    &lt;div class="bibo:abstract"&gt;
      &lt;p&gt;
Recent clinical studies suggest sustained treatment effects of interleukin-1β (IL-1β)-blocking therapies in type 2 diabetes mellitus. The underlying mechanisms of these effects, however, remain underexplored. Using a quantitative systems pharmacology modeling approach, we combined ex vivo data of IL-1β effects on β-cell function and turnover with a disease progression model of the long-term interactions between insulin, glucose, and β-cell mass in type 2 diabetes mellitus. We then simulated treatment effects of the IL-1 receptor antagonist anakinra. The result was a substantial and partly sustained symptomatic improvement in β-cell function, and hence also in HbA1C, fasting plasma glucose, and proinsulin-insulin ratio, and a small increase in β-cell mass. We propose that improved β-cell function, rather than mass, is likely to explain the main IL-1β-blocking effects seen in current clinical data, but that improved β-cell mass might result in disease-modifying effects not clearly distinguishable until &amp;gt;1 year after treatment. 
    &lt;/p&gt;
    &lt;/div&gt;
  &lt;/div&gt;
  &lt;div class="dc:publisher"&gt;
    &lt;p&gt;This model is hosted on 
  &lt;a href="http://www.ebi.ac.uk/biomodels/"&gt;BioModels Database&lt;/a&gt;
  and identified by: 
  &lt;a href="http://identifiers.org/biomodels.db/MODEL1604270002"&gt;MODEL1604270002&lt;/a&gt;.&lt;/p&gt;
    &lt;p&gt;To cite BioModels Database, please use: 
  &lt;a href="http://identifiers.org/pubmed/26225232" title="Latest BioModels Database publication"&gt;BioModels:
  Content, Features, Functionality and Use.&lt;/a&gt;&lt;/p&gt;
  &lt;/div&gt;
  &lt;div class="dc:license"&gt;
    &lt;p&gt;To the extent possible under law, all copyright and related or
  neighbouring rights to this encoded model have been dedicated to
  the public domain worldwide. Please refer to 
  &lt;a href="http://creativecommons.org/publicdomain/zero/1.0/" title="Access to: CC0 1.0 Universal (CC0 1.0), Public Domain Dedication"&gt;CC0
  Public Domain Dedication&lt;/a&gt; for more information.&lt;/p&gt;
  &lt;/div&gt;
&lt;/body&gt;</ns2:description>
    <ns3:title xmlns:ns3="http://purl.org/dc/elements/1.1/">Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms</ns3:title>
    <ns4:thumbnail xmlns:ns4="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000621.omex/BIOMD0000000621.png"/>
    <ns5:thumbnail xmlns:ns5="http://www.collex.org/schema#"
       rdf:resource="http://omex-library.org/BIOMD0000000621.omex/curation_image.png"/>
  </rdf:Description>
  <rdf:Description rdf:about="local:00001">
    <ns6:identifier xmlns:ns6="http://purl.org/dc/elements/1.1/"
       rdf:resource="http://identifiers.org/doi/10.1038/psp.2014.16"/>
    <ns7:label xmlns:ns7="http://www.w3.org/2000/01/rdf-schema#">R Palmér, E Nyman, M Penney, A Marley, G Cedersund &amp; B Agoram. Effects of IL-1β-Blocking Therapies in Type 2 Diabetes Mellitus: A Quantitative Systems Pharmacology Modeling Approach to Explore Underlying Mechanisms. CPT: Pharmacometrics &amp;amp; Systems Pharmacology 3, 6 (2014).</ns7:label>
  </rdf:Description>
</rdf:RDF>

